Reduction of aspirin-induced ulcers by a new imidazoline anti-inflammatory agent.
We have previously described the anti-inflammatory and low ulcerogenic actions of the formamidine pesticide, chlordimeform (CDM). In this study, the related basic compound, CDMI [2-(2-methyl-4-chlorophenylamino)-2-imidazoline], also demonstrated potent anti-edema (vs. carrageenin) and low ulcerogenic activity. A nonulcerogenic i.p. dose of CDMI reduced aspirin (ASA)-induced ulcers [lesion index (L.I.): 25.8 for ASA alond vs. 5.3 for ASA + i.p. CDMI]; prevented stress-induced ulcers in mice; and decreased acid secretion (by 90% in the Shay rat preparation). A mildly ulcerogenic oral dose (0.6 mmol/kg) of CDMI prevented stress ulcers, but did not reduce ASA ulcers. A nonulcerogenic oral dose (0.15 mmol/kg) of CDMI did reduce ASA ulcers (L.I.: 24.5 for ASA alone vs. 14.7 for ASA + oral CDMI). Thus, CDMI is a unique anti-inflammatory agent with additional anti-secretory and ulcer-reducing actions.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001241:Aspirin / Q000037:antagonists & inhibitors*; D003000:Clonidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004347:Drug Interactions; D005744:Gastric Acid / Q000378:metabolism; D008297:Male; D051379:Mice; D051381:Rats; D011919:Rats, Inbred Strains; D012149:Restraint, Physical; D013276:Stomach Ulcer / Q000517:prevention & control*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; C033863:2-(2-methyl-4-chlorophenylamino)-2-imidazoline; D003000:Clonidine; D001241:Aspirin